Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period

Mitsumoto H, 1988, Recent advances in pathogenesis and therapeutic trials. Arch Neurol, 45, 189

Dawbarn D, 2003, Neuropathol Appi Neurobiol, 29, 211, 10.1046/j.1365-2990.2003.00487.x

Drachman DB, Frank K, Dykes-Hoberg M et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol 2002; 52: 771–778.

Aboussouan LS, 2001, Muscle & Nerve, 24, 403, 10.1002/1097-4598(200103)24:3<403::AID-MUS1013>3.0.CO;2-3

10.1212/WNL.53.5.1059

The International WHO., 1968, Classification of Diseases

The International WHO., 1993, Classification of Diseases, 5

10.1080/146608200300079536

10.1212/WNL.24.8.721

10.1080/01621459.1958.10501452

Cox DR., 1972, J R Stat Soc B, 34, 187

10.1007/BF00328503

Testa D, 1992, Clin Neurol Neurosurg, 94, 7, 10.1016/0303-8467(92)90110-O

Beghi E, 2000, A randomised controlled trial of recombinant interferon-beta-la in ALS. Neurology, 54, 469

Kurtzke IF., 1991, Risk factors in amyotrophic lateral sclerosis, 56, 245

Eisen A, 1993, Muscle & Nerve, 16, 27, 10.1002/mus.880160107

Sar M, 1977, Science, 197, 77, 10.1126/science.867053

Weiner LP., 1980, Arch Neurol, 37, 129, 10.1001/archneur.1980.00500520027002

Chancellor AM, 1993, J Neurol, 240, 339, 10.1007/BF00839964

Chiò A, 2002, Early symptom progression rate is related to ALS outcome. Neurology, 59, 99

Gubbay SS, 1985, A study of its presentation and prognosis. I Neurol, 232, 295

Haverkamp LJ, 1995, Validation of a scoring system and a model for survival prediction. Brain, 118, 707

Mulder DW, 1976, Mayo Clin Proc, 51, 537

Traynor BJ, 2000, Clinical features of amyotrophic lateral sclerosis according to El Escorial and Airlie House diagnostic criteria. A population-based study. Arch Neurol, 57, 1171

Norris F, 1993, Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci, 118, 48

Louwerse ES, 1997, Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors. J Neurol Sci, 152, S10

10.1080/1028415021000033767

Iwasaki Y, 2002, Clin Neurol Neurosurg, 104, 87, 10.1016/S0303-8467(01)00188-3

Househam E, 2000, J Neurol Sci, 180, 76, 10.1016/S0022-510X(00)00418-4

del Águila MA, 2003, A population-based study. Neurology, 60, 813

Miller RG, 1999, Gelinas DF et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 52, 1311

Worms PM., 2001, J Neurol Sci, 191, 3, 10.1016/S0022-510X(01)00630-X

Sorenson EJ, 2002, Neurology, 59, 280, 10.1212/WNL.59.2.280

Chiò A, 2001, Amyotrophic lateral sclerosis care in Italy: a nationwide study in neurological centres. J Neurol Sci, 191, 145